#Duravyu

Health

Eyepoint Faces Setback as Amylyx Celebrates Success

By Editor • August 18, 2026 • 1 min read

Eyepoint's trial setback for Duravyu contrasts with Ocular Therapeutix's stock rise, while Novartis withdraws reimbursement plans for another new drug in Canada.

Health

Eyepoint's Vision Treatment Trial Falls Short, Stock Takes a Hit

By Editor • August 17, 2026 • 1 min read

Eyepoint's experimental vision treatment trial fails to meet expectations, affecting its stock and plans for regulatory approval.